Allergy
Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy.
Philippe Bégin, Motohiro Ebisawa, Antonella Muraro, Gideon Lack, Matthew Greenhawt, Rima Rachid, Brian P Vickery, Aikaterini Anagnostou, Jeffrey Leflein, Kirsten P Perrett, Ivan Bottoli, Benjamin Ortiz, Motoi Hosoe, Eva Schlosser, Wei Wang
Published: 202610.1111/all.70206
Abstract
BACKGROUND: The growing burden of food allergy globally has been accompanied by increasing demand for effective treatments. Ligelizumab is a humanised anti-IgE monoclonal antibody that can strongly inhibit allergic pathways. This phase 3 study evalua…
Preview only. Read the full abstract at the source